Transgene SA became the latest contender to jump on board the interferon-free bandwagon in hepatitis C virus (HCV) therapy, as it unveiled interim data from a 153-patient Phase II trial of its therapeutic vaccine TG-4040, which indicated that the vaccine, when administered in combination with the standard therapy of pegylated interferon alpha plus ribavirin (PEG/Riba) was twice as effective in eliciting a complete early virologic response (cEVR) as standard therapy alone.Transgene is now seeking a series of nonexclusive partnerships to enable it to test TG-4040 in a variety of inte